Tag: PCSK9 inhibitor

EU approves Repatha for reduction of CV risk

by Selina McKee | May 23, 2018 | News | 0

The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).

Amgen’s Repatha clears blocked arteries, shows study

by Selina McKee | Nov 16, 2016 | News | 0

Amgen has presented clinical data indicating that its PCSK9 inhibitor Repatha could help to reverse heart disease by removing atherosclerotic plaques, showing for the first time that the effect of this class of drugs may go further than reducing cholesterol alone.